Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

The study, published by the McCullough Foundation, says the deaths reported in VAERS are estimated to be underreported by a ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...